Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Melior Discovery has announced that the FDA has approved its investigational new drug application for the clinical development of its kinase activator, MLR-1023, for the treatment of type 2 diabetes.
Subscribe to our email newsletter
MLR-1023 was discovered and developed internally using Melior’s indications discovery platform, theraTRACE.
Andrew Reaume, president and CEO of Melior, said: “We are delighted to have been given the go-ahead by the FDA to advance MLR-1023 into clinical development. This investigational new drug (IND) application represents a major milestone for Melior Discovery, and underscores the productivity of our theraTRACE indications discovery engine. In addition to MLR-1023, we have a number of other programs also progressing towards the clinic.”